000 01452 a2200421 4500
005 20250516175949.0
264 0 _c20150423
008 201504s 0 0 eng d
022 _a1029-2403
024 7 _a10.3109/10428194.2013.861066
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJourdan, Eric
245 0 0 _aA multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma.
_h[electronic resource]
260 _bLeukemia & lymphoma
_cSep 2014
300 _a2013-7 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntineoplastic Agents
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aIndoles
_xadministration & dosage
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMultiple Myeloma
_xdrug therapy
650 0 4 _aProtein Kinase Inhibitors
_xadministration & dosage
650 0 4 _aRetreatment
650 0 4 _aTreatment Outcome
700 1 _aLeblond, Veronique
700 1 _aMaisonneuve, Hervé
700 1 _aBenhadji, Karim A
700 1 _aHossain, Anwar M
700 1 _aNguyen, Tuan S
700 1 _aWooldridge, James E
700 1 _aMoreau, Philippe
773 0 _tLeukemia & lymphoma
_gvol. 55
_gno. 9
_gp. 2013-7
856 4 0 _uhttps://doi.org/10.3109/10428194.2013.861066
_zAvailable from publisher's website
999 _c23221227
_d23221227